ArticleJournal of applied biomedicine2025
Exosomes from LPS-stimulated macrophages alleviate neuroinflammatory responses by reducing pyroptosis in systemic lipopolysaccharide-induced mice.
Article in Journal of applied biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Central nervous system (CNS) inflammation occurs in cognitive dysfunction, but the underlying mechanisms remain unclear. The newly discovered pattern of cell death in recent years is called pyroptosis, which is distinguished from apoptosis and necrosis, and is mainly dependent on caspase-1 mediated inflammatory response. Stem-derived exosomes have immunomodulatory and immunosuppressive effects. In the present study, we aimed to investigate the exosomes (Ex) secreted by lipopolysaccharide (LPS)-stimulated macrophages (LPS-Ex) to attenuate the neuroinflammatory response caused by systemic LPS stimulation by attenuating pyroptosis. We studied lipopolysaccharide (LPS)-induced cognitive impairment and neuroinflammation in C57BL/6 mice by behavioral testing, immunofluorescence, enzyme-linked immunosorbent assay (ELISA), Western blotting, and other methods. We found that LPS-Ex can reduce the level of inflammatory factors, down-regulate the pyroptosis pathway and the inflammatory pathway of NF-κB, and improve the inflammatory response of neurological function in mice. The conclusion is that LPS-Ex relieves neuroinflammation by reducing pyroptosis. It can be used as a novel therapeutic strategy for neuroprotection and functional recovery in the onset of central nervous system inflammation.
Indexed as
Identifiers
41403229What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.